Elicio Therapeutics (Nasdaq: ELTX), a clinical-stage biotech developing immunotherapies for KRAS-driven cancers, announced that its management will participate in one-on-one meetings at the Wells Fargo 21st Annual Healthcare Conference, held September 8-10, 2026, in Boston, MA. One-on-one meetings are scheduled for Thursday, September 10, 2026, and interested parties are asked to contact their Wells Fargo representative to arrange a meeting.
Loading...
Loading translation...
Positive
None.
Negative
None.
Market Context
An active S-3/A shelf registering up to $400,000,000 places this conference notice alongside a discl...
Analysis
An active S-3/A shelf registering up to $400,000,000 places this conference notice alongside a disclosed financing framework. The announcement adds no trial or financial results; the filing record also reports substantial doubt about going-concern status.
Key Figures
Conference edition:21st annualConference dates:September 8-10, 2026Meeting date:September 10, 2026+1 more
Russell 2000 and Russell 3000 additions produced a zero price reaction.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Negative reactions aligned with earnings and offering news, while clinical-study activation and index inclusion produced divergences.
Key Terms
kras
1 terms
krasmedical
"developing next-generation immunotherapies for KRAS-driven cancers"
KRAS is a gene that makes a protein acting like a switch to control cell growth; certain changes (mutations) can lock that switch on and drive uncontrolled cell multiplication, which is a common cause of many cancers. Investors care because drugs or tests targeting KRAS mutations can create large markets or avoidable risks depending on trial results and regulatory decisions, much like a key product feature deciding a gadget’s commercial success.
BOSTON, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that management will participate in one-on-one meetings at the upcoming Wells Fargo 21st Annual Healthcare Conference, taking place September 8-10, 2026, in Boston, MA.
If you are interested in arranging a 1×1 meeting with management at the conference, please contact your Wells Fargo representative.
About Elicio Therapeutics
Elicio Therapeutics, Inc. (Nasdaq: ELTX) is a clinical-stage biotechnology company advancing next-generation immunotherapies for the treatment of KRAS-driven cancers, including mKRAS-positive pancreatic and colorectal cancers. Elicio intends to build on recent clinical findings in the personalized cancer immunotherapy space to develop effective, off-the-shelf immunotherapies. Elicio’s AMP technology aims to enhance the education, activation, and amplification of cancer-specific T cells relative to conventional immunotherapy strategies, with the goal of promoting durable cancer immunosurveillance in patients. Elicio’s ELI-002 7P lead program is an off-the-shelf immunotherapy candidate targeting the most common KRAS mutations, which drive approximately 25% of all solid tumors. Off-the-shelf immunotherapy approaches have the potential benefits of low cost, rapid, commercial-scale manufacturing, and rapid availability of drug to patients, especially in neo-adjuvant settings and for prophylaxis in high-risk patients, contrary to personalized immunotherapy approaches. Elicio’s pipeline includes additional off-the-shelf therapeutic cancer immunotherapy candidates, including ELI-007 and ELI-008, which target BRAF-driven cancers and p53 hotspot mutations, respectively. For more information, please visit www.elicio.com.
What did Elicio Therapeutics (ELTX) announce regarding the Wells Fargo 21st Annual Healthcare Conference in 2026?
Elicio Therapeutics announced that its management will participate in one-on-one meetings at the Wells Fargo 21st Annual Healthcare Conference in Boston. According to Elicio, these meetings will occur during the event scheduled for September 8-10, 2026, with sessions on Thursday, September 10.
When will Elicio Therapeutics (ELTX) hold one-on-one meetings at the Wells Fargo 2026 Healthcare Conference?
Elicio Therapeutics plans to hold one-on-one meetings with investors on Thursday, September 10, 2026. According to the company, these meetings take place during the Wells Fargo 21st Annual Healthcare Conference, which runs from September 8-10, 2026, in Boston, Massachusetts.
How can investors arrange a one-on-one meeting with Elicio Therapeutics (ELTX) at the Wells Fargo 21st Annual Healthcare Conference?
Investors can arrange a one-on-one meeting with Elicio Therapeutics by contacting their Wells Fargo representative. According to Elicio, Wells Fargo coordinates the meeting schedule for the conference, so interested participants should work through their existing Wells Fargo point of contact.
Where is the Wells Fargo 21st Annual Healthcare Conference featuring Elicio Therapeutics (ELTX) being held in 2026?
The Wells Fargo 21st Annual Healthcare Conference featuring Elicio Therapeutics is being held in Boston, Massachusetts. According to the company, the conference is scheduled for September 8-10, 2026, with Elicio’s one-on-one investor meetings set for Thursday, September 10, 2026.
What type of company is Elicio Therapeutics (Nasdaq: ELTX) that is attending the Wells Fargo 2026 Healthcare Conference?
Elicio Therapeutics is a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers. According to Elicio, its participation in the Wells Fargo 21st Annual Healthcare Conference involves management holding one-on-one meetings with interested parties to discuss the company’s programs and strategy.
